Hormonal Treatment and Cardiovascular Risk Profile in Transgender Adolescents
| Autor: | Martin den Heijer, Renée de Mutsert, Maartje Klaver, Maria A T C van der Loos, Daniel T Klink, Chantal M. Wiepjes, Jos W. R. Twisk, Joost Rotteveel |
|---|---|
| Přispěvatelé: | Internal medicine, Epidemiology and Data Science, ACS - Atherosclerosis & ischemic syndromes, AGEM - Endocrinology, metabolism and nutrition, Amsterdam Movement Sciences - Rehabilitation & Development, Amsterdam Movement Sciences - Restoration and Development, APH - Aging & Later Life, Amsterdam Movement Sciences, Pediatric surgery, ACS - Diabetes & metabolism, Amsterdam Reproduction & Development (AR&D), APH - Quality of Care, APH - Methodology, APH - Health Behaviors & Chronic Diseases |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Pediatric Obesity medicine.medical_specialty Adolescent Risk Assessment Cohort Studies Gonadotropin-Releasing Hormone Young Adult 03 medical and health sciences 0302 clinical medicine Insulin resistance 030225 pediatrics Internal medicine Prevalence Humans Medicine Gonadal Steroid Hormones Dyslipidemias Retrospective Studies business.industry Retrospective cohort study medicine.disease Obesity Confidence interval Blood pressure Cardiovascular Diseases Pediatrics Perinatology and Child Health Homeostatic model assessment Female business Transsexualism Dyslipidemia Cohort study |
| Zdroj: | Klaver, M, de Mutsert, R, van der Loos, M A T C, Wiepjes, C M, Twisk, J W R, den Heijer, M, Rotteveel, J & Klink, D T 2020, ' Hormonal Treatment and Cardiovascular Risk Profile in Transgender Adolescents ', Pediatrics, vol. 145, no. 3, e20190741 . https://doi.org/10.1542/peds.2019-0741 Pediatrics, 145(3):e20190741. American Academy of Pediatrics Pediatrics, 145(3). AMER ACAD PEDIATRICS |
| ISSN: | 0031-4005 |
| DOI: | 10.1542/peds.2019-0741 |
| Popis: | BACKGROUND AND OBJECTIVES: The effects of endocrinological treatment on cardiovascular risk profile in transgender adolescents are unknown. In this retrospective cohort study, we aim to investigate these effects and assess obesity and dyslipidemia prevalence in transgender adolescents at 22 years compared with peers. METHODS: Changes in BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), glucose, homeostatic model assessment for insulin resistance (HOMA-IR), and lipid values during treatment, along with the prevalence of obesity and dyslipidemia at 22 years, were recorded in 71 transwomen and 121 transmen who started gonadotropin-releasing hormone agonists in their adolescence (15 years), with a subsequent addition of sex hormones (17 years). RESULTS: In transwomen, changes in BMI (+3.0; 95% confidence interval [CI] 1.6 to 4.4), SBP (−2 mm Hg; 95% CI −7 to 3), DBP (+10 mm Hg; 95% CI 7 to 14), glucose (0.0 mmol/L; 95% CI −0.2 to 0.2), HOMA-IR (+0.6; 95% CI −0.6 to 1.9), and lipid values were similar or more favorable compared with peers. The same was true for transmen regarding changes in BMI (+2.3; 95% CI 1.7 to 2.9), SBP (+7 mm Hg; 95% CI 3 to 10), DBP (+7 mm Hg; 95% CI 5 to 10), glucose (+0.1 mmol/L; 95% CI −0.1 to 0.3), HOMA-IR (−0.2; 95% CI −0.8 to 0.3), and lipid values. At age 22, obesity prevalence was 9.9% in transwomen, 6.6% in transmen, 2.2% in ciswomen, and 3.0% in cismen. CONCLUSIONS: Generally, endocrinological treatment in transgender adolescents is safe regarding cardiovascular risk. Because obesity is more prevalent in transgender adolescents compared with peers, body weight management should be important during the medical trajectory. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|